Phase 3Active, not recruiting
A Clinical Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis
An Open-label, Single-arm Clinical Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis
- Sponsor
- Taisho Pharmaceutical Co., Ltd. (Industry)
- Enrolment
- 34 enrolled
- Conditions
- Hyperphosphatemia Patients on Hemodialysis
- Interventions
- TS-172 20~60 mg/day
- Ages
- adults, older adults
- Registry
- NCT07548840
Full record on ClinicalTrials.gov
From the registry
An open-label, single-arm clinical study of TS-172 in hyperphosphatemia patients on hemodialysis
Primary outcomes
- Achievement rate of the target serum phosphorus level
History
Primary completion expected
Last registry update
Started
Registered